Shelley A. Hartman
Directeur Général chez Aegle Therapeutics Corp.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
William L. Rust | M | - |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | 11 ans |
Robert Williamson | M | 58 |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | 11 ans |
Evangelos V. Badiavas | M | - |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | 11 ans |
Lonnie Moulder | M | 66 |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
James Topper | M | 62 |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | - |
Bernie Treidl | M | - |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | - |
Robert P. Ryan | M | - |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
Heidi Kempinski | F | - |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | 4 ans |
Elona Baum | F | - |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
David Schimel | M | - |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
Arup Roy | M | - |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | - |
Min-Jung Choi | F | - |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | - |
Jerry Baty | M | - |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Cheryl Balaban | F | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
Holger Weis | M | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | 5 ans |
Holger Weis | M | 61 |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | 5 ans |
Alan M. Sebulsky | M | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
Eric Hecht | M | 62 |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
M. Judah Folkman | M | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
B. Johnson | F | 72 |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
Paul Brooke | M | 77 |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | 3 ans |
Charles L. Brown | M | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | 10 ans |
Matthew Likens | M | 71 |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | 5 ans |
Lou Ann Beggs | F | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | 3 ans |
Matthew Rebold | M | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
Kevin O'Reilly | M | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
Rudyard L. Istvan | M | - |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 27 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Shelley A. Hartman
- Réseau Personnel